The in vivo testing on animals for the purpose of safety assessment is being increasingly replaced by the in silico and in vitro approaches. Due to the complexity of actual in vivo systems it is not yet possible to replace them by a single in vitro or in silico test. Instead integrated approaches are needed that are able to address multiple events in the adverse outcome pathway (AOP) under questions. 

The session on »Integrated in silico and in vitro approaches to safety assessment« will focus on new developments and use of such integrated approaches. In particular we will learn how causal networks could be utilized to quantify the conections in adverse outcome pathways. Furthermore the use of advanced transcriptomic data analysis for investigation of the pathway activations due to exposure to cadmium will be presented. Finally, we will also see how drug-induced liver injury (DILI) could be predicted using a combination of in vitro, in vivo and in silico models.